Journal article
A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients
AMIA Summits on Translational Science proceedings, Vol.2020, pp.664-673
05/30/2020
PMCID: PMC7233072
PMID: 32477689
Abstract
Simvastatin is a commonly used medication for lipid management and cardiovascular disease, however, the risk of adverse events (AEs) with its use increases via drug-drug interaction (DDI) exposures. Patients were extracted if initially diagnosed with cardiovascular disease and newly initiated simvastatin therapy. The cohort was divided into a DDI-exposed group and a non-DDI exposed group. The DDI-exposed group was further divided into gemfibrozil, clarithromycin, and erythromycin exposure groups. The outcome was defined as a composite of predefined AEs. Our results show that the simvastatin-DDI group had a higher illness burden with longer simvastatin exposure time and more medical care follow-up compared with the simvastatin-non-DDI exposed group. AEs occurred more frequently in subjects exposed to interacting drugs with a higher risk for clarithromycin and erythromycin exposed subjects than for gemfibrozil subjects.
Details
- Title: Subtitle
- A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients
- Creators
- Jin WangChih-Lin ChiWendy L. St. PeterAngie CarlsonMatt LothPrajwal Mani PradhanYue LiangWei-Yu ChenTatiana LenskaiaJennifer G. RobinsonTerrence J Adam
- Resource Type
- Journal article
- Publication Details
- AMIA Summits on Translational Science proceedings, Vol.2020, pp.664-673
- Publisher
- American Medical Informatics Association
- PMID
- 32477689
- PMCID
- PMC7233072
- ISSN
- 2153-4063
- eISSN
- 2153-4063
- Language
- English
- Date published
- 05/30/2020
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984364521002771
Metrics
17 Record Views